Temporal expression of agrB, cidA and alsS in the early development of Staphylococcus aureus UAMS‐1 biofilm formation and the structural role of extracellular DNA and carbohydrates
This article is protected by copyright. All rights reserved. (Source: FEMS Immunology and Medical Microbiology)
Source: FEMS Immunology and Medical Microbiology - February 17, 2014 Category: Microbiology Authors: R. Grande, L. Nistico, K. Sambanthamoorthy, M. Longwell, A. Iannitelli, L. Cellini, A. Di Stefano, L. Hall Stoodley, P. Stoodley Tags: Research Paper Source Type: research
A first-year dornase alfa treatment impact on clinical parameters of patients with cystic fibrosis: the Brazilian cystic fibrosis multicenter study
CONCLUSIONS: The treatment with dornase alfa promoted the maintenance of pulmonary function parameters and was associated with a significant reduction of emergency room visits due to pulmonary exacerbations in the six to 11 years age group, with better clinical scores in the >14 age group, one year after the intervention. OBJETIVO: Relatar el impacto clínico del primer año de tratamiento con dornasa alfa conforme a la franja de edad, en una cohorte de pacientes brasileños con fibrosis quística (FC). MÉTODOS: El presente estudio analizó datos de 152 pacientes elegibles, de 16 centros de referencia para FC, l...
Source: Revista Paulista de Pediatria - January 14, 2014 Category: Pediatrics Source Type: research
Predictors and Outcome of Low Initial Forced Expiratory Volume in 1 Second Measurement in Children with Cystic Fibrosis
Conclusions: Some children with cystic fibrosis may present with poor lung function early in life and continue to have subnormal lung function associated with reduced body mass index, more frequent hospitalization, and higher rates of infection. Such children may benefit from careful evaluation and close follow-up. (Source: The Journal of Pediatrics)
Source: The Journal of Pediatrics - January 13, 2014 Category: Pediatrics Authors: Gulnur Com, John L. Carroll, Maria Melguizo Castro, Xinyu Tang, Supriya Jambhekar, Ariel Berlinski Tags: Original Articles Source Type: research
Medical management of chronic rhinosinusitis in cystic fibrosis: A systematic review
Conclusion:
Dornase alfa and, to a lesser extent, topical steroids demonstrated significant benefits in the medical treatment CRS in CF. There was a lack of evidence to support antibiotic therapy in the outcomes assessed. Further high quality studies should be carried out to determine the efficacy of various medical therapies for CRS in CF. (Source: The Laryngoscope)
Source: The Laryngoscope - November 7, 2013 Category: ENT & OMF Authors: Jonathan Liang, Thomas Higgins, Stacey L. Ishman, Emily F. Boss, James R. Benke, Sandra Y. Lin Tags: Letter to the Editor Source Type: research
Inhalation solutions — Which ones may be mixed? Physico-chemical compatibility of drug solutions in nebulizers — Update 2013
Abstract: Many patients suffering from chronic respiratory diseases rely on inhalation therapy with nebulizers. About 25% of patients who need to inhale several different drugs per day save time by mixing them for simultaneous inhalation. This review presents a comprehensive overview of the available data concerning physico-chemical compatibility of commonly mixed nebulizer solutions and suspensions. Information is based on our in vitro studies and a thorough literature search.Results indicate that many nebulizer solutions/suspensions are mixable without provoking incompatibilities. However, certain excipients contained in...
Source: Journal of Cystic Fibrosis - October 30, 2013 Category: Respiratory Medicine Authors: Wolfgang Kamin, Frank Erdnüss, Irene Krämer Tags: Review Source Type: research
Nebulized and oral thiol derivatives for pulmonary disease in cystic fibrosis.
CONCLUSIONS: We found no evidence to recommend the use of either nebulized or oral thiol derivatives in people with cystic fibrosis. There are very few good quality trials investigating the effect of these medications in cystic fibrosis, and further research is required to investigate the potential role of these medications in improving the outcomes of people with cystic fibrosis.
PMID: 23852992 [PubMed - as supplied by publisher] (Source: Cochrane Database of Systematic Reviews)
Source: Cochrane Database of Systematic Reviews - July 12, 2013 Category: Journals (General) Authors: Tam J, Nash EF, Ratjen F, Tullis E, Stephenson A Tags: Cochrane Database Syst Rev Source Type: research
Small airway deposition of dornase alfa during exacerbations in cystic fibrosis; a randomized controlled clinical trial
ConclusionsThis study did not detect a difference if inhaled dornase alfa was targeted to small versus large airways during a RTE. However, the 95% confidence interval for the change in FEF75 was wide. Further studies are needed to improve the effectiveness of RTE treatment in CF. Pediatr Pulmonol. © 2013 Wiley Periodicals, Inc. (Source: Pediatric Pulmonology)
Source: Pediatric Pulmonology - July 3, 2013 Category: Respiratory Medicine Authors: E.M. Bakker, S. Volpi, E. Salonini, B. Müllinger, P. Kroneberg, M. Bakker, W.C.J. Hop, B.M. Assael, H.A.W.M. Tiddens Tags: Original Article: Cystic Fibrosis Source Type: research
Physiotherapy for cystic fibrosis in Australia: Knowledge and acceptance of the Consensus Statement recommendations
ConclusionsPhysiotherapists are aware of treatment recommendations for CF in common areas of practice such as airway clearance and exercise. However, knowledge of recommendations is lower for specialized areas of practice and outside of CF centres. Strategies to improve awareness and uptake of the Consensus Statement among physiotherapists outside of CF centres are required. (Source: Respirology)
Source: Respirology - April 25, 2013 Category: Respiratory Medicine Authors: Anne E. Holland, Brenda M. Button, Tags: ORIGINAL ARTICLE Source Type: research
Small-airways deposition of dornase alfa in children with asthma and persistent airway obstruction
Despite modern antiasthma treatment, 30% to 70% of asthmatic patients do not gain optimal asthma control, and up to one third of patients continue to show abnormal spirometric values. Mucus retention can contribute to persistent small-airways obstruction in patients with childhood asthma. Sputum in asthmatic patients is known to be composed of activated and degenerated inflammatory cells, mucoproteins, and free DNA released from disintegrated inflammatory cells. Recombinant human DNase (dornase alfa) is a mucolytic agent that reduces sputum viscosity by hydrolyzing extracellular DNA in sputum. Case reports suggest that dor...
Source: Journal of Allergy and Clinical Immunology - March 29, 2013 Category: Allergy & Immunology Authors: E. Marije Bakker, Els C. van der Wiel-Kooij, Bernhard Müllinger, Philipp Kroneberg, Wim C.J. Hop, Harm A.W.M. Tiddens Tags: Letters to the Editor Source Type: research
New therapy of pleural empyema by deoxyribonuclease.
We report two cases of intrapleural administration of Pulmozyme (alfa dornase - deoxyribonuclease (HOFFMANN-LA ROCHE AG) in dosage 2×2.5mg with a significant improvement caused by changes in pus viscosity.
PMID: 23332886 [PubMed - as supplied by publisher] (Source: Braz J Infect Dis)
Source: Braz J Infect Dis - January 15, 2013 Category: Infectious Diseases Authors: Kacprzak G, Majewski A, Kolodziej J, Rzechonek A, Gürlich R, Bobek V Tags: Braz J Infect Dis Source Type: research
